The battle between over-the-counter generic and branded drugs is going from the pharmacy aisles to the Internet.
Recently, generic-drug specialist Perrigo (PRGO 2.87%) announced a marketing campaign aimed at educating consumers and explaining the advantages that generic over-the-counter products have over their branded, more expensive counterparts. Will this strategy immediately grow the company's revenue? Conversely, does this spell doom for branded drugmakers such as Merck (MRK 0.44%) or Pfizer? Health-care analyst Max Macaluso discusses these topics in the following video.
